Showing results (1-10 of 77) with videos related to

Sort By:
Pageof 8
Breast Care (Basel, Switzerland)|December 14, 2017
Are We Ready to Use ESR1 Mutations in Clinical Practice?Rinath Jeselsohn
Frontiers in Oncology|January 23, 2023
ESR1 fusions and therapeutic resistance in metastatic breast cancerZsuzsanna Nagy, Rinath Jeselsohn
Frontiers in Oncology|March 23, 2023
Corrigendum: ESR1 fusions and therapeutic resistance in metastatic breast cancerZsuzsanna Nagy, Rinath Jeselsohn
Elife|March 25, 2016
How drug resistance takes shapeRinath Jeselsohn, Myles Brown
Cancer Research|February 2, 2021
The ESR1 Mutations: From Bedside to Bench to BedsideFrancisco Hermida-Prado, Rinath Jeselsohn
Cell Chemical Biology|October 20, 2023
HATS off to KAT6A/B inhibitors: A new way to target estrogen-receptor-positive breast cancerRinath Jeselsohn, Kornelia Polyak
Cancer Cell|September 10, 2021
Restoring order at the cell cycle border: Co-targeting CDK4/6 and CDK2Rinath Jeselsohn, Rachel Schiff, Albert Grinshpun
Hematology/Oncology Clinics of North America|November 26, 2022
The Clinical Utility of ESR1 Mutations in Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerAlbert Grinshpun, Zachary M Sandusky, Rinath Jeselsohn
Current Oncology Reports|April 5, 2017
The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast CancerRinath Jeselsohn, Carmine De Angelis, Myles Brown, et al.
Pageof 8